FORGOT YOUR DETAILS?

Avexa announces EAP with Link on schedule

by / Thursday, 11 September 2014 / Published in News

Avexa Limited – Manufacture of ATC product for Named Patient Scheme completed

Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 9th September 2014

 

Melbourne, Australia, Tuesday 9th September 2014: Australian biotechnology company Avexa Limited
[ASX:AVX] today announced that the manufacture of ATC product intended for its Early Access / Named
Patient Scheme has been completed successfully, on schedule and is now ready for shipment to LINK
Healthcare’s facility in Singapore as soon as the necessary regulatory paperwork is complete.
LINK’s facility in Singapore will act as the hub for world-wide distribution of ATC through the Early Access /
Named Patient Scheme, which is expected to be operational by the end of calendar year 2014. For further
information on Link Healthcare or the EAP go to: www.linkhealthcare.co
“This is a significant milestone for Avexa and ATC. Patients who are running out of options for HIV treatment,
will now have access to a new agent that has activity against drug-resistant HIV and which has been
demonstrated to be well tolerated.” said Dr Jonathan Coates, Avexa’s CSO and interim CEO. “We look
forward to working with LINK Healthcare in facilitating access to ATC for those patients in need, wherever they
may be.”

About Avexa Limited

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and
commercialization of small molecules for the treatment of infectious diseases. Avexa’s key projects include
apricitabine (ATC) for the treatment of drug resistant HIV, an HIV integrase program and an antibiotic program
for antibiotic-resistant bacterial infections.

For more information:
Mr Iain Kirkwood
Chairman

Ph: +61 408 473 496
Dr Jonathan Coates
CSO and Interim CEO
Ph: +61 3 8888 1040

www.avexa.com.au

 

About LINK Healthcare (Australia, New Zealand, Southern Africa, Singapore, Hong Kong & Japan)

LINK Healthcare is a privately owned specialist pharmaceutical and medical technologies business. LINK’s mission is to strive for excellence in the marketing of vitally important and unique range of specialists products that enhance the well-being of people throughout the regions of Australia, New Zealand, Asia and Southern Africa.

LINK provides exceptional regulatory, sales, marketing, customer service and supply chain infrastructure and is partnered with major blue chip pharmaceutical companies from around the world, allowing the company to offer a unique and substantial portfolio of ‘medicine that matters.’

LINK Healthcare has an extensive range of prescription pharmaceuticals in essential therapeutic areas including Allergy, Anaphylaxis, Analgesia/Anaesthesia, Anti-infective, Anti-retroviral, Cardiology, Endocrinology, ENT, Gastroenterology, Intensive care, Metabolic disease, Neurology, Oncology, Orphan Drugs, Palliative care, Psychiatry, Radiography, Transplantation and Toxicology.
In Australia and Southern Africa the group also commercialize a unique range of medical technology products focused in the specialist areas of advanced wound care, diabetes and point of care testing.

For more information about LINK Healthcare visit www.linkhealthcare.com.au

FOR FURTHER INFORMATION
Contact LINK Healthcare on 61 (2) 8401 9777
Corporate and Media Enquiries:
Mr John Bacon
Executive Chairman

 

TOP